Ascentage Pharma Group International (AAPG) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ascentage Pharma Group International stock (AAPG) is currently trading at $22.32. Ascentage Pharma Group International PS ratio (Price-to-Sales) is 4.58. Analyst consensus price target for AAPG is $49.14. WallStSmart rates AAPG as Sell.
- AAPG PE ratio analysis and historical PE chart
- AAPG PS ratio (Price-to-Sales) history and trend
- AAPG intrinsic value — DCF, Graham Number, EPV models
- AAPG stock price prediction 2025 2026 2027 2028 2029 2030
- AAPG fair value vs current price
- AAPG insider transactions and insider buying
- Is AAPG undervalued or overvalued?
- Ascentage Pharma Group International financial analysis — revenue, earnings, cash flow
- AAPG Piotroski F-Score and Altman Z-Score
- AAPG analyst price target and Smart Rating
Ascentage Pharma Group International
📊 No data available
Try selecting a different time range
Smart Analysis
Ascentage Pharma Group International (AAPG) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Ascentage Pharma Group International (AAPG) Key Strengths (0)
Supporting Valuation Data
Ascentage Pharma Group International (AAPG) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Revenue declining -71.60%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 19.3x book value
Very low institutional interest at 0.08%
Premium valuation at 4.6x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Ascentage Pharma Group International (AAPG) Detailed Analysis Report
Overall Assessment
This company scores 13/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 0 register as strengths (avg 0/10) while 8 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (4.58), Price/Book (19.29) suggest expensive pricing. Growth concerns include Revenue Growth at -71.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -159.70%, Operating Margin at -237.00%, Profit Margin at -296.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -159.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -71.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AAPG Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AAPG's Price-to-Sales ratio of 4.58x trades at a 28% premium to its historical average of 3.57x (70th percentile). The current valuation is 22% below its historical high of 5.87x set in Mar 2026, and 172% above its historical low of 1.68x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~2.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ascentage Pharma Group International (AAPG) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ascentage Pharma Group International is in a turnaround phase, with management focused on restoring profitability. Revenue reached 391M with 72% decline year-over-year. The company is currently unprofitable, posting a -296.8% profit margin.
Key Findings
Spending 135% of revenue (529M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 72% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -296.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ascentage Pharma Group International.
Bottom Line
Ascentage Pharma Group International is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:19:10 PM
About Ascentage Pharma Group International(AAPG)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.